Prakt. lékáren. 2013; 9(6): 234-239

Cystic fibrosis and current treatment options

Eliška Tajovská
Nemocniční lékárna, FN Motol, Praha

Cystic fibrosis (CF) is a serious hereditary disease, which represents a significant burden for patients and their families, and shortens the life

of patients. The disease manifests with pulmonary and extrapulmonary manifestations, a characteristic symptom of CF is a high concentration

of chloride in the sweat of patients. Mucostasis, obstruction and chronic infection occur in the lungs. Treatment of pulmonary manifestations

has a major impact on the quality and length of the life of patients. This is especially good care of the airway through respiratory

physiotherapy and drugs that reduce the viscosity of mucus in the airways and in the treatment of serious lung infections with antibiotics.

In the digestive tract CF leads to failure of exocrine pancreatic function, consequently the absorption of fat from food is not possible and

it leads to malnutrition. Treatment of extrapulmonary manifestations includes substitution of pancreatic enzymes, especially nutrition of

patients, treatment of liver disease and early treatment of complications such as diabetes, osteoporosis, intestinal obstruction, and others.

As a clinical entity, this disease is known since the 40th of last century, originally a clearly fatal diagnosis in the first year of life. Thanks to

improved diagnostic methods and intense treatments are now up to 50% of patients live for the fourth decades of life. The purpose of this

article is to show the current CF treatment options with regard to the involvement of pharmacist in the care of patients with CF.

Keywords: cystic fibrosis, exacerbation, respiratory physiotherapy, pancreatic insufficiency, nutrition

Published: December 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tajovská E. Cystic fibrosis and current treatment options. Praktické lékárenství. 2013;9(6):234-239.
Download citation

References

  1. Skalická V, et al. Cystická fibróza. Současný pohled na diagnostiku, možnosti léčby a prognózu. Postgrad Med 2010; 12(7): 817-823.
  2. Skalická V. Nové dimenze v diagnostice a léčbě cystické fibrózy: od novorozeneckého screeningu k léčbě podstaty onemocnění. Vox Pediatiriae 2012; 12(3): 26-29.
  3. Vávrová V, et al. Cystická fibróza. Praha, Grada 2006: 516.
  4. Milavetz G, Smith JJ. Cystic fibrosis. In: DiPiro J T, et al. Pharmacotherapy: A Pathophysiologic Approach, Sixth Edition. NY, McGraw-Hill Companies 2005: 591-601.
  5. Bush AA, et al. Respiratory Research, Volume 34: Cystic Fibrosis in the 21st Century. Basel, Karger Publishers 2006: 341.
  6. Zemanick E T, et al. Measuring and improving respiratory outcomes in cystic fibrosis lung disease: Opportunities and challenges to therapy. Journal of Cystic Fibrosis 2010; 9(1): 1-16. Go to original source... Go to PubMed...
  7. Kerem E, et al. Standarts of care for patients with cystic fibrosis: a European consensus. Journal of Cystic Fibrosis 2005; 4(1): 7-26. Go to original source... Go to PubMed...
  8. Pediatric Formulary Committee. British National Formulary for Children 2012-2013. Pharmaceutical Press 2012: 862.
  9. Souhrn údajů o přípravku, dostupné na http://www.sukl.cz.
  10. Heijerman H, et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European Consensus. Journal of Cystic Fibrosis 2009; 8(5): 298-315. Go to original source... Go to PubMed...
  11. Elborn J S, Hodson M, Bertram C. Implementation of European standards of care for cystic fibrosis - Control and Treatment of Infection. Journal of Cystic fibrosis 2009; 8(3): 211-217. Go to original source... Go to PubMed...
  12. Flume E A, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176(10): 957-969. Go to original source... Go to PubMed...
  13. Uluer A Z, et al. Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis. Journal of Cystic Fibrosis 2013; 12(1): 54-59. Go to original source... Go to PubMed...
  14. Henke MO, Ratjen F. Mucolytics in cystic fibrosis. Pediatric Respiratory Rewievs 2007; 8(1): 24-29. Go to original source... Go to PubMed...
  15. Prickett M, Jain M. Gene therapy in cystic fibrosis. Translational Research 2013; 161(4): 255-264. Go to original source... Go to PubMed...




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.